Results 211 to 220 of about 53,085 (229)

Bortezomib

Reactions Weekly, 2021
openaire   +1 more source

Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma: Updated Time-to-Event Analyses of the Multicenter Phase 2 PINNACLE Study

Annals of Oncology, 2009
Benjamin Djulbegovic, B S Kahl, E Epner
exaly  

Clinical Activity of Bortezomib in Relapsed/Refractory MALT Lymphomas: Results of a Phase II Study of the International Extranodal Lymphoma Study Group (IELSG)

Annals of Oncology, 2011
Stefano Luminari, Giovanni Martinelli, Liliana Devizzi   +2 more
exaly  

Bortezomib and Gemcitabine in Relapsed or Refractory Hodgkin's Lymphoma

Annals of Oncology, 2008
Jason Mendler, Craig T Jordan, J W Friedberg   +2 more
exaly  

Bortezomib

Reactions Weekly, 2013
openaire   +1 more source

Bortezomib

Reactions Weekly, 2014
openaire   +1 more source

First-Line Bortezomib Benefits Patients With Multiple Myeloma

Nature Reviews Clinical Oncology, 2009
Evangelos Terpos, Athanasios Dimopoulos
exaly  

Phase I Study of Proteasome Inhibitor Bortezomib Plus CHOP in Patients With Advanced, Aggressive T-Cell or NK/T-Cell Lymphoma

Annals of Oncology, 2008
Jooryung Huh, B-Y Ryoo, H J Kang
exaly  

Bortezomib Formulations

2012
USAYAPANT ARUNYA, BOWMAN DAVID
openaire   +2 more sources

Phase II Study of Bortezomib in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma: CALGB 90207

Annals of Oncology, 2008
Susan Halabi, J E Rosenberg, E J Small
exaly